Subcuject

Subcuject was a privately held technology company that functioned as a virtual organisation. The company developed an innovative and proprietary wearable device platform for bolus injection for delivery of biologics.

Headquarters
Subcuject ApS
Nordre Strandvej 119, F1
DK-3150 Hellebaek
Denmark

Phone / Contact

T: +45 2122 7772
E: [email protected]

Connect

Articles by Subcuject

LOW-COMPLEXITY, EASY-TO-USE WEARABLE INJECTION PLATFORM

Jesper Roested discusses the increasing prevalence of biologics formulated for large-volume injections in drug development and how wearable devices, including Subcuject’s offering, may be a better solution for delivering these drugs than scaled-up conventional autoinjectors.

MEETING EMERGING STAKEHOLDER NEEDS WITH THE SUBCUJECT WEARABLE BOLUS INJECTOR

Tony Bedford looks at the emerging market for on-body injectors coupled with stakeholder needs and introduces the Subcuject wearable bolus injector, which is designed to accommodate these requirements.

Claus Schmidt Moeller

SUBCUJECT WBI: LOW-COST, LARGER VOLUME, HIGH-VISCOSITY WEARABLE BOLUS INJECTOR – USING STANDARD GLASS PRIMARY PACKAGING

Claus Schmidt Moeller introduces the company’s wearable bolus injector for single use and discusses the advantages of the device.

STABILITY OF A WEARABLE INJECTOR POWERED BY OSMOSIS

Jesper Roested and Tomas Gundberg present engineering test data on Subcuject’s wearable bolus injector, based on an osmotic drive system, demonstrating that the device presents a solution to the need for an inexpensive, mass-producible wearable injector.

APPLICATION OF CFD IN THE DEVELOPMENT OF A WEARABLE BOLUS INJECTOR

Marcus Hall, Björn Ullbrand and Claus Schmidt Møller describe the use of computational fluid dynamics (CFD) as the primary design and analysis tool in the development of a wearable bolus injector.

Claus Schmidt Moeller

DEVELOPMENT OF AN OSMOTIC LARGER VOLUME WEARABLE BOLUS INJECTOR

Claus Schmidt Moeller provides an overview of the mechanism, functionality and applications of the company’s osmotic, single-use, low-cost, versatile wearable bolus injector.

A PATIENT CENTRIC AND PHARMA COMPANY CENTRIC PREFILLED WEARABLE BOLUS INJECTOR

Jesper Roested explains why the pharma/biotech drug development process often means device selection occurs after Phase II despite the advantages of earlier selection being well understood, and how this then precludes the selection of novel primary packaging and delivery systems.

WEARABLE INJECTORS: THE PERCEPTION OF INHERENT EXPENSE AND COMPLEXITY

There is a widespread belief that wearable injectors are too expensive and complex to really take off as a commercially viable method of drug delivery. Jesper Roested tackles the causes of this belief, and explains why it is not truly the case.

Top